Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision medicine, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by Legend Capital. The funds will allow the company to double down on mass spectrometry multi-omics applications and innovative drug development, as well as preclinical research analysis.
Funding Details
The proceeds will also be used to ramp up product research and development (R & D), team building, and market expansion. APT Bio plans to create a precision medicine layout driven by big data and artificial intelligence (AI).
Company Background
Founded in 2004 by the Shanghai Institutes for Biological Sciences from CAS, APT Bio boasts an innovation technology center, data center, and clinical testing center in Shanghai, Yiwu of Zhejiang, and Taizhou of Jiangsu. The company has a combined 20,000 square meters of space. Additionally, APT Bio has established a large cohort multi-omics research technology platform, biopharmaceutical preclinical pharmacy research analysis and small-scale production platform, mass spectrometry clinical detection, companion diagnostic platform, and AI big data algorithm technology platforms. This enables the company to conduct business in technology services, biopharmaceutical CRO services, and mass spectrometry clinical testing services.-Fineline Info & Tech
